Boothbay Fund Management’s Blueprint Medicines BPMC Stock Holding History

Boothbay Fund Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-350,000	Closed	-$31M	–	1467
2025 Q1	$31M	Buy	350,000 +209,800	+150%	+$20.5M	0.82%	9
2024 Q4	$12.2M	Buy	+140,200	New	+$12.8M	0.3%	62
2022 Q3	–	Sell	-7,800	Closed	-$394K	–	2257
2022 Q2	$394K	Hold	7,800	–	–	0.01%	1307
2022 Q1	$498K	Buy	+7,800	New	+$560K	0.01%	1296
2020 Q3	–	Sell	-161	Closed	-$1.26M	–	1051
2020 Q2	$1.26M	Buy	161 +92	+133%	+$6.22K	0.09%	316
2020 Q1	$404K	Buy	+69	New	+$4.44K	0.03%	494
2019 Q1	–	Sell	-264	Closed	-$1.42M	–	758
2018 Q4	$1.42M	Buy	264 +152	+136%	+$9.24K	0.21%	96
2018 Q3	$874K	Buy	+112	New	+$7.78K	0.09%	232
2017 Q2	–	Sell	-45,200	Closed	-$1.81M	–	679
2017 Q1	$1.81M	Buy	+45,200	New	+$1.62M	0.34%	45

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boothbay Fund Management's BPMC Position: Q2 2025 in Review

Boothbay Fund Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 36,454 shares — an estimated $3.23M sold.

Boothbay Fund Management first reported a position in BPMC in Q3 2018 and held it in 11 quarters. The position peaked at $4.32M in Q4 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Boothbay Fund Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Boothbay Fund Management sold 36,454 Blueprint Medicines shares in Q2 2025, an estimated $3.23M.
Boothbay Fund Management first reported a position in Blueprint Medicines in Q3 2018 and held it in 11 quarters.
Boothbay Fund Management's Blueprint Medicines position peaked at $4.32M in Q4 2024.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.